Anixa Biosciences (NASDAQ:ANIX) CEO Acquires $17,300.00 in Stock

Anixa Biosciences Inc (NASDAQ:ANIX) CEO Amit Kumar acquired 5,000 shares of the company’s stock in a transaction on Monday, July 20th. The shares were bought at an average price of $3.46 per share, with a total value of $17,300.00. Following the completion of the purchase, the chief executive officer directly owned 640,812 shares of the company’s stock, valued at approximately $2,217,209.52. This represents a 0.79% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Amit Kumar also recently made the following trade(s):

• On Friday, July 24th, Amit Kumar bought 3,000 shares of Anixa Biosciences stock. The stock was purchased at an average price of $3.73 per share, for a total transaction of $11,190.00.
• On Monday, July 27th, Amit Kumar bought 3,188 shares of Anixa Biosciences stock. The stock was purchased at an average price of $3.37 per share, for a total transaction of $10,743.56.
• On Monday, July 27th, Amit Kumar bought 5,000 shares of Anixa Biosciences stock. The stock was purchased at an average cost of $3.44 per share, for a total transaction of $17,200.00.
• On Friday, July 10th, Amit Kumar bought 5,000 shares of Anixa Biosciences stock. The shares were purchased at an average price of $3.04 per share, with a total value of $15,200.00.
• On Friday, June 12th, Amit Kumar bought 21,000 shares of Anixa Biosciences stock. The shares were purchased at an average price of $2.50 per share, with a total value of $52,500.00.

Anixa Biosciences Stock Up 2.3%

NASDAQ:ANIX opened at $3.56 on Friday. The firm has a market cap of $121.12 million, a PE ratio of -11.48 and a beta of 0.59. Anixa Biosciences Inc has a 12 month low of $2.32 and a 12 month high of $5.46. The company’s 50-day moving average price is $2.96 and its two-hundred day moving average price is $2.92.

Anixa Biosciences (NASDAQ:ANIX) last posted its quarterly earnings data on Wednesday, June 10th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.03. On average, research analysts expect that Anixa Biosciences Inc will post -0.31 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on ANIX. Citigroup reaffirmed a “buy” rating on shares of Anixa Biosciences in a report on Friday, June 12th. HC Wainwright reissued a “buy” rating on shares of Anixa Biosciences in a research note on Friday, June 12th. Weiss Ratings restated a “sell (e+)” rating on shares of Anixa Biosciences in a report on Wednesday, June 17th. Zacks Research upgraded Anixa Biosciences from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 21st. Finally, D. Boral Capital reaffirmed a “buy” rating and issued a $10.00 price target on shares of Anixa Biosciences in a report on Tuesday, June 30th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $8.50.

Institutional Trading of Anixa Biosciences

Hedge funds and other institutional investors have recently modified their holdings of the stock. NewEdge Advisors LLC acquired a new position in Anixa Biosciences during the 2nd quarter worth $33,000. Northwestern Mutual Wealth Management Co. boosted its position in Anixa Biosciences by 2,000.0% in the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 10,500 shares of the company’s stock valued at $35,000 after buying an additional 10,000 shares during the last quarter. Cetera Investment Advisers acquired a new stake in shares of Anixa Biosciences in the 4th quarter valued at $35,000. Benjamin Edwards Inc. acquired a new stake in shares of Anixa Biosciences in the 2nd quarter valued at $37,000. Finally, Marshall Wace LLP acquired a new stake in shares of Anixa Biosciences in the 2nd quarter valued at $39,000. Institutional investors and hedge funds own 29.13% of the company’s stock.

About Anixa Biosciences

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.